Lyndsay Harris, MD, Oncology, Cleveland, OH, UH Cleveland Medical Center

LyndsayNorineHarrisMD

Oncology Cleveland, OH

Hematologic Oncology

Professor, Medicine, Case Western Reserve Univ Sch of Med

Dr. Harris is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Harris' full profile

Already have an account?

Education & Training

  • Georgetown University HospitalFellowship, Medical Oncology, 1991 - 1994
  • University of Alberta Faculty of MedicineClass of 1988

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2012 - 2022
  • CT State Medical License
    CT State Medical License 2006 - 2012
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Capivasertib in Patients with an AKT1 E17K-Mutated Tumor  
    Kevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology

Press Mentions

  • Genomic Study of 6000 NCI-MATCH Cancer Patients Leads to New Clinical Trial Benchmarks
    Genomic Study of 6000 NCI-MATCH Cancer Patients Leads to New Clinical Trial BenchmarksOctober 13th, 2020
  • New Antibody-Drug Conjugate Shows Promising Activity in Salivary Gland Tumors
    New Antibody-Drug Conjugate Shows Promising Activity in Salivary Gland TumorsJanuary 7th, 2020
  • Arm Z1D of NCI-MATCH Shows Promise for Nivolumab Beyond Colorectal Cancer
    Arm Z1D of NCI-MATCH Shows Promise for Nivolumab Beyond Colorectal CancerDecember 23rd, 2019
  • Join now to see all

Grant Support

  • Targeted Combinations For Her2- Positive Breast Cancer BiologyNational Cancer Institute2008–2009
  • P-2: Target Combinations For HER2 - Positive Breast CancerNational Cancer Institute2005–2007
  • Core--Tissue And PathologyNational Cancer Institute2000–2002
  • Erbb2/P53 And Taxane Chemotherapy For Breast CancerNational Cancer Institute1999–2000

Committees

  • Co-chair, Expert Panel, American Society of Clinical Oncology (ASCO) 2015 - Present

Hospital Affiliations